Lowering blood sugar levels in obese women can partially restore reproductive hormone levels, which improves fertility, according to a new study. The study’s findings were published in the Journal of Endocrinology.

The study indicates that altered levels of reproductive hormones in a well-established mouse model of obesity can be partially restored by a generic type 2 diabetes drug that lowers blood glucose levels. Many obese women who experience fertility problems also have altered levels of reproductive hormones. Currently, there is no effective therapy to deal with it.

The development of a therapy that not only improves women’s metabolic health but also treats obesity-related infertility would be a significant advance with the potential to improve the quality of life for many.

Although fertility problems in obese women are well established, effective and targeted therapies to address them remain lacking. Obesity is a growing health epidemic, which means more women are being affected by fertility difficulties.

Obesity-related fertility issues are complex but evidence suggests that, in part, they may be linked to changes in energy metabolism, leading to altered levels of reproductive hormones that can disrupt the menstrual cycle and ovulation. Obese people are at higher risk of developing type 2 diabetes and often have high blood sugar levels, as well as other metabolic changes.

MC4R The gene knock-out mouse is a well-organized model of obesity, which exhibits irregular reproductive cycles with altered hormone levels leading to a decline in fertility. The mouse reproductive cycle is similar to that of humans, with a similar pattern of hormone level changes, although it is much shorter in duration, so MC4R KO The mouse is a good, representative model for the initial investigation of metabolism and reproductive function.

Dapagliflozin It is a drug commonly used to treat type 2 diabetes, where it lowers blood sugar levels and improves other markers of metabolic health but its effects on reproductive health and fertility are yet to be investigated .

In this study, Professor Chen and his colleagues from the University of Queensland in Australia looked at obesity. MC4R KO examined the effects of dapagliflozin treatment on metabolic health and reproductive hormone levels in a mouse model. After only 8 weeks of treatment blood glucose levels were normal, body weight was reduced, the reproductive cycle returned to normal and levels of reproductive hormones and ovulation were partially restored compared to non-treated rats Was.

We often see low fertility in obese women in clinical practice, comments the primary author, Dr. Cui, a visiting fellow at Chengdu Women’s and Children’s Hospital in China, so this research offers hope for future, effective treatments. Is.

Professor Chen comments, “These data suggest that normalizing blood glucose metabolism with dapagliflogen in obesity may be a promising route to at least partially restore reproductive function.” It may improve fertility in women where no other successful therapy is currently available.

However, Professor Chen cautions, these studies were conducted in rats and more work is needed to confirm that these findings can be replicated effectively in females. However, people who are obese have a higher risk of developing type 2. Diabetes, so the known health benefits of correcting blood sugar levels may be extended to improving fertility in those affected.

The team now intends to investigate the therapeutic benefits of using dapagliflogen to improve reproductive function by examining the molecular pathways involved, which may identify better targets for future fertility treatments in women.

read this also – Click to read the news of your state / city before the newspaper